Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study.
about
Nicotine receptors and depression: revisiting and revising the cholinergic hypothesisSmoking and suicide: a brief overviewDrug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric DisordersBeyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewMolecular mechanisms underlying behaviors related to nicotine addictionReview of pharmacological treatment in mood disorders and future directions for drug development.Molecules and circuits involved in nicotine addiction: The many faces of smokingCognitive Dysfunction, Affective States, and Vulnerability to Nicotine Addiction: A Multifactorial PerspectiveMecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disordersDual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsHow cigarette smoking may increase the risk of anxiety symptoms and anxiety disorders: a critical review of biological pathways.Varenicline improves mood and cognition during smoking abstinence.Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys.Functional neuroimaging in geriatric depression.Functional brain imaging of nicotinic effects on higher cognitive processes.The potent and selective α4β2*/α6*-nicotinic acetylcholine receptor partial agonist 2-[5-[5-((S)Azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol demonstrates antidepressive-like behavior in animal models and a favorable ADME-tox profile.Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior.Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited.Expression of the 5-HT1A serotonin receptor in the hippocampus is required for social stress resilience and the antidepressant-like effects induced by the nicotinic partial agonist cytisineα4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties.Ventral tegmental area cholinergic mechanisms mediate behavioral responses in the forced swim test.Examining antidepressant drug response by smoking status: why is it important and how often is it done?Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380.Design and Synthesis of Nicotinic Acetylcholine Receptor Antagonists and their Effect on Cognitive Impairment.Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral statesTreatment-resistant depression: therapeutic trends, challenges, and future directions.Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.Perspective: Translational studies on glutamate and dopamine neurocircuitry in addictions: implications for addiction treatment.Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant.Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behaviorMultiple Nicotinic Acetylcholine Receptor Subtypes in the Mouse Amygdala Regulate Affective Behaviors and Response to Social Stress.Potential therapeutic uses of mecamylamine and its stereoisomers.Varenicline augmentation in depressed smokers: an 8-week, open-label study.Cigarette Smoking and Tryptophan Hydroxylase 2 mRNA in the Dorsal Raphe Nucleus in Suicides.Cytisine-based nicotinic partial agonists as novel antidepressant compounds.Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5IA single photon emission computed tomography.
P2860
Q24634536-C6CA62D0-3E6C-4296-B6E5-760852C134FEQ24655785-DCAFD973-1963-4DAA-85F6-C887D55058AFQ26748728-A9022C95-6F56-4237-AAE6-35AAB160D11CQ26782993-EFEFAEE8-80D7-42DE-8647-045F6A76D2B2Q26851972-4877FE8C-8F94-44B1-A06A-25E545B39B9BQ26853509-3148A783-9941-415D-BAB1-B517D01D1F52Q27008063-0807C545-B432-4725-A4FF-8AEAB4398063Q28071876-3F4DF005-D1B7-499B-BF9B-8545FCF89E6FQ28263028-5CC6F470-1183-4BFB-AC59-B77DE2DBB5A7Q28305100-9EDE8084-444C-4D7E-9294-77E7934FEBA1Q30453328-700D5409-FC41-4097-836F-DA04598E53A2Q30483957-07B8B0C6-B176-4DC7-BC17-374B21F24959Q33716723-B1A2448F-657A-46ED-AF6E-A88BD49ADE5EQ33746863-B83ABCCC-57AA-4DE0-BDAB-8960F4FC579BQ33887659-C17C4A91-6A5C-4703-B37D-A4AA8EAADCFBQ33935792-A7809A9F-AAAD-4773-BEB7-8EAEA522AA52Q34286851-36F129A2-EE65-4067-9E49-BE3788B48993Q34304101-31A3F243-058A-497F-AE05-CFABBDB228C6Q34394190-965471D8-95BF-484A-AF3F-94FF331ACB0BQ35054681-0DC3BB83-6E11-422A-85A5-8CB2F59FFE75Q35089398-0152EA87-9B0C-49E5-9A64-B4EAAB6FA1B0Q35581667-7924CFED-A384-4AA5-BFB6-BC7FD1A16260Q35646906-B70BBEAF-CADE-4787-8F0D-7BD5EA521A74Q35667964-F8A03A69-2E6C-43F2-A859-9828BEBFD97AQ35699233-08AC3B0A-9883-44A2-9B26-60F5A644E8F9Q35733853-12390E50-FD80-469D-8F50-13D8AD0805ABQ35738694-9C974C79-9729-4B76-A81D-67168B54CF25Q35802079-0B7CFF11-9A4E-462E-AD71-02D666A059E6Q35997448-A3CF5F7F-9E50-4F1C-B093-127EBD7D9EBBQ36136238-073A32D8-CFCD-4131-A88C-CA40CAEC9A1FQ36277604-DA6B402A-A3DD-4D86-8481-EC1BD931DE12Q36387711-37F9C554-279D-4B6C-BAE5-7A325E26FBA3Q36514290-A9F73B85-ABF1-4D45-8979-8BD21A68E8ADQ36653933-7E4F93E9-1AC4-4D76-ADD1-10B95494AD12Q36799026-D75A2D08-5A56-451A-A3E8-53E9E17069C3Q36949979-17C00F0F-80E0-4B23-AA01-00FFBCFD3220Q37025397-4395F97A-0878-4742-9A8E-A233BD52519CQ37037372-4D373897-C295-4FCC-863D-C14920FF0BE9Q37162147-8C72F185-B6A2-4B6B-84D0-CB22805066BEQ37248791-0150BD9C-9F1D-4B2B-852D-C992567F7CD5
P2860
Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Nicotinic antagonist augmentat ...... disorder: a preliminary study.
@en
Nicotinic antagonist augmentat ...... disorder: a preliminary study.
@nl
type
label
Nicotinic antagonist augmentat ...... disorder: a preliminary study.
@en
Nicotinic antagonist augmentat ...... disorder: a preliminary study.
@nl
prefLabel
Nicotinic antagonist augmentat ...... disorder: a preliminary study.
@en
Nicotinic antagonist augmentat ...... disorder: a preliminary study.
@nl
P2093
P1476
Nicotinic antagonist augmentat ...... disorder: a preliminary study.
@en
P2093
Andrea H Weinberger
Jennifer C Vessicchio
Kristi A Sacco
R Douglas Shytle
Tony P George
P304
P356
10.1097/JCP.0B013E318172B49E
P407
P577
2008-06-01T00:00:00Z